Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intrinsa Advisory Cmte. Decision Should Not Affect Dapoxetine, PPD Says

This article was originally published in The Pink Sheet Daily

Executive Summary

An FDA advisory committee's recommendation against approval of Procter & Gamble's testosterone patch Intrinsa should not impact Johnson & Johnson's premature ejaculation therapy dapoxetine, PPD says

You may also be interested in...



J&J Submits Dapoxetine NDA For Premature Ejaculation

The company is waiting to see if the selective serotonin reuptake inhibitor will receive priority review. Submission is slightly earlier than expected.

J&J Submits Dapoxetine NDA For Premature Ejaculation

The company is waiting to see if the selective serotonin reuptake inhibitor will receive priority review. Submission is slightly earlier than expected.

P&G Intrinsa Gets No Satisfaction; Potential Risks Outweigh Sexual Benefits

FDA’s Reproductive Health Drugs Advisory Committee votes unanimously Dec. 2 that current efficacy and safety data for the female sexual dysfunction therapy do not support approval. Committee recommends completion of safety studies in pre- and postmenopausal women prior to approval.

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel